Roche Invests in Blueprint Medicines to Develop Lung-Cancer Drug

Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp.

The two companies will develop pralsetinib, a therapy for people with RET-altered nonsmall cell lung cancer, various types of thyroid cancer and other solid tumours.

The Swiss drug company said it will pay $675 million in cash upfront, as well as a $100 million equity investment in Blueprint Medicines.

The U.S.-based drug company is eligible to receive up to $927 million in potential milestones, plus royalties on net product sales outside the U.S.

Roche said the agreement gives it exclusive rights for global co-development and commercialization outside the U.S. and excluding Greater China.

https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/news/Roche-Invests-in-Blueprint-Medicines-to-Develop-Lung-Cancer-Drug-30919705/